Nader Sanai, MD

Nader Sanai, MD, discusses a phase 1 trial investigating BDTX-1535 in patients with recurrent, EGFR-mutated high-grade glioblastoma.

Dr. Nader Sanai presents the findings of a phase 0/1 trigger trial (NCT06072586) that evaluates the CNS penetration of BDTX-1535 in patients with recurrent high-grade gliomas and EGFR mutations.

Nader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.